US RESIDENTS: Please note that the information contained in this page is not intended for US residents. Please visit our US webpage. www.actelion.us

OUR PAH FRANCHISE

OPSUMIT®

OPSUMIT®

Opsumit is commercially available in over 45 markets, including the US (since November 2013), Germany (since January 2014) and Japan (since June 2015). The registration process for other countries is ongoing.

TRACLEER®

TRACLEER®

Tracleer is commercially available in over 60 markets, including the US (since November 2001), the EU (since May 2002) and Japan (since April 2005).

UPTRAVI®

UPTRAVI®

Uptravi is commercially available in over 20 markets, including the US (since January 2016) and Germany (since June 2016). The registration process for other countries is ongoing.

VELETRI®

VELETRI®

Veletri is commercially available in 17 markets, including the US since 2010, Switzerland and Canada (marketed as Caripul®) since 2012, Japan (marketed as Epoprostenol “ACT”) since 2013, and some European countries since 2013. The registration process for other countries is ongoing.

VENTAVIS®

VENTAVIS®

Actelion has marketed Ventavis in the US since 2007. Elsewhere it is marketed by Bayer Healthcare.

OUR SPECIALTY PRODUCTS

    

"I find my work motivational because at the end of the day I know that I am doing my part to better other people's lives."

Facilities Coordinator, Facilities Management